This is Archived Content

This content is available for historical purposes only. It may not reflect the current state of science or language from the National Institute on Drug Abuse (NIDA). Find the latest information on substance use, health, and NIDA research at

Cite this article

NIDA. (2013, May 10). NIDA and AstraZeneca partner to develop potential addiction medication. Retrieved from

press ctrl+c to copy


May 10, 2013

From concept to medication to treatment graphic

NIDA and AstraZeneca, a global research-based biopharmaceutical company, have joined efforts to explore a novel medication to treat drug addiction. The scientific partnership will explore a specific molecule that modulates the activity of glutamate – an excitatory neurotransmitter. Preclinical studies with this class of molecule indicate that it could be effective for treating a range of mental disorders, including abuse of substances ranging from tobacco to cocaine.

A key strategy of NIDA’s medications development program is to work with pharmaceutical and biotechnology companies to translate basic research findings into medications that treat drug addiction. Further details on NIDA’s efforts in this area can be found at:

For more information, contact the NIDA press office at or 301-443-6245.